1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Gujarat Terce Laboratories Limited

Gujarat Terce Laboratories Limited

BBSE:GUJTERC
34.00
INR
-2.91
(-7.88%)
2.67EPS
13.34P/E
280.49MMarket Cap
Gujarat Terce Laboratories Limited
BSE:GUJTERC
(Bombay Stock Exchange)

Recent

price

34.00

P/E

ratio

13.34

div

yld

- -

ROIC.AI

2010
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
36.96
136.08
108.41
38.87
35.69
33.68
34.08
39.1
41.82
50.6
33.93
54.09
63.05
64.65
67.65
63.06
58.96
Revenue per Share
0.26
0.18
0.26
0.32
0.12
-0.91
-0.02
0.36
0.58
0.37
-3.4
1.18
-2.25
0.33
-1.32
2.92
2.7
Basic EPS, GAAP
- -
- -
- -
0.4
1
0.22
0.33
6.17
-0.83
-2.79
-0.9
-3.45
-0.05
3.4
4.12
2.24
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
12.08
- -
14.34
14.74
14.87
13.96
13.55
14.02
14.6
14.97
10.33
11.5
9.25
9.58
8.73
12.49
- -
Book Value per Share
12.08
- -
14.34
14.74
14.87
13.96
13.55
14.02
14.6
14.97
10.33
11.5
9.25
9.58
8.73
12.49
- -
Tangible Book Value per Share
5
7
7
7
7
7
7
7
7
7
7
7
7
7
7
8
8
Basic Weighted Avg Shares
185
987
790
288
265
250
253
290
310
375
252
401
468
480
502
475
456
Sales/Revenue/Turnover
3.13
0.62
0.89
2.15
2.35
-0.11
-0.43
0.48
0.89
1.18
-10.31
3.47
-5.26
1.93
7.01
7.12
6.23
Operating Margin (%)
2
3
3
3
2
2
2
2
2
2
2
3
4
4
4
4
4
Depreciation Expense
1
1
2
2
1
-7
- -
3
4
3
-25
9
-17
2
-10
22
21
Net Income, GAAP
55.94
23.55
30.25
29.49
68.89
- -
168.67
16.75
- -
36.64
- -
- -
- -
55.24
128.86
27.39
29.65
Effective Tax Rate (%)
0.7
0.13
0.24
0.83
0.34
-2.7
-0.06
0.93
1.39
0.74
-10.01
2.17
-3.57
0.51
-1.95
4.64
4.58
Profit Margin (%)
75
- -
84
85
89
69
65
24
26
26
3
23
-6
-9
-6
35
- -
Working Capital
31
- -
65
57
55
55
55
2
1
2
4
23
15
9
3
- -
- -
LT Debt
59
- -
106
109
110
104
101
104
108
111
77
85
69
71
65
97
- -
Total Equity
- -
- -
- -
1.11
0.46
- -
-0.07
0.85
- -
2.35
- -
- -
- -
3.21
-10.98
22.76
- -
Return on Invested Capital (%)
- -
- -
- -
2.61
1.12
- -
-1.22
3.05
- -
3.47
- -
- -
- -
4.18
-11.78
25.11
- -
Return on Capital (%)
- -
- -
- -
2.23
0.83
-6.3
-0.15
2.65
4.07
2.52
-26.85
10.77
-21.71
3.49
-14.41
27.17
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
13
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
339
241
280

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
144
- -
Cash, Cash Equivalents & STI
- -
42
- -
Accounts Receivable, Net
- -
49
- -
Inventories
- -
37
- -
Total Current Liabilities
- -
109
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
13
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.29%
7.34%
50.18%
Free Cash Flow
-497.71%
-1,375.82%
-44.94%
Net Income, GAAP
-438.29%
-273.54%
-324.98%
Sales/Revenue/Turnover
8.86%
15.55%
-5.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
119
133
127
123
502
2026
109
129
123
114
475
2027
90
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.1
2
1.36
-4.57
-1.32
2026
-0.06
1.89
0.95
0.13
2.92
2027
-0.23
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Gujarat Terce Laboratories Limited develops, manufactures, markets, and distributes a broad portfolio of pharmaceutical medicines and healthcare products across key therapeutic areas including respiratory system disorders, antibiotics, pain therapy, gastrointestinal therapy, gynaecological products, nutraceuticals, and ayurvedic formulations; core offerings encompass tablets such as Acolate-M (levocetirizine di-HCl 5 mg + montelukast sodium 10 mg), Aziter 500 (azithromycin 500 mg), Algin-P (aceclofenac 100 mg + paracetamol 325 mg), and OMRON Plus Syrup (ferrous ascorbate eq. to elemental iron 30 mg + folic acid 550 mcg), capsules, oral suspensions like Acolate DS (paracetamol 250 mg + phenylephrine hydrochloride 5 mg + chlorpheniramine maleate 2 mg / 5 ml), injections such as Cesafe-TZ (ceftriaxone sodium 500 mg + tazobactam sodium 62.50 mg), ointments, and ayurvedic specialties including Instalins and Urikal Syrup. The company, founded in 1985 and headquartered in Ahmedabad, Gujarat, India, operates an ISO 9001-certified, fully automated manufacturing facility compliant with international regulatory standards and maintains a strong domestic presence across 13 Indian states alongside exports to emerging markets in Eastern and Western Africa, ASEAN countries, and LATAM regions. Recent developments include the installation of a new state-of-the-art mixing and branding machine with 200kg/lot capacity to enhance production capabilities, significant financial growth with EBITDA rising 114%, cash profit increasing 101%, and EPS up 94% as reported in recent periods, alongside ongoing new product launches and R&D investments in promising pipeline products to address unfulfilled healthcare needs; the company also held its 40th Annual General Meeting in August 2025 and continues to prioritize secondary sales growth, inventory optimization, and collection efficiency for sustainable expansion.